InsidersTradesSigma
EDAP TMS SA Stock: price and management transactions · United States · SEC (Form 4)
Follow the EDAP TMS SA share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, EDAP TMS SA has published 2 public disclosures. Market capitalisation: €161.9m. The latest transaction was disclosed on 13 May 2026 (Attribution). Among the most active insiders: Shah Sanket. The full history is accessible without an account.
2
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
0 ops.
Sell Volume
3Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 24,200 of 25,750 companies
17.3
score / 100
Value12
Quality22
FCF yld-14%
Earn yld-18%
EV/EBITDA·
ROE-124%
Gross mgn43%
Net mgn-41%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 13 May 2026
Declarations2 total
67,500 shares0Common StockSEC:0001829126-26-005047:0
67,500 shares0Common StockSEC:0001829126-26-005047
2 of 2 declarations
About EDAP TMS SA
EDAP TMS SA is a French medical device company focused on minimally invasive ultrasound-based therapies. The company is listed on the Nasdaq in the United States, making it relevant for U.S. equity investors even though its corporate roots and headquarters are in Vaulx-en-Velin, near Lyon, France. Founded in 1979, EDAP has built its business over several decades around therapeutic ultrasound and urology, gradually sharpening its strategic focus toward higher-value robotic energy-based therapies. The company’s core investment thesis is now centered on Focal One®, its robotic High-Intensity Focused Ultrasound (HIFU) platform for prostate tissue ablation. Focal One integrates imaging, robotics, and precise non-invasive energy delivery to target tissue without open surgery. That positions EDAP as a niche but important player in focal therapy for prostate cancer, a market where physicians are looking for less invasive options that may preserve quality-of-life outcomes relative to traditional radical procedures. This is where EDAP differentiates itself: not as a broad medtech conglomerate, but as a specialized technology company with a clinically oriented platform and a focused commercial message. EDAP still maintains legacy or non-core activities, including extracorporeal shock wave lithotripsy (ESWL) systems for urinary stones and certain third-party product distribution businesses. However, management has clearly been prioritizing HIFU as the main growth engine. The company’s international footprint includes direct operations and commercialization in the United States, Europe, and select other markets, supported by a commercial and clinical network that helps drive system placements and recurring disposables revenue. Recent developments have reinforced that strategic direction. In 2025, EDAP launched Focal One i, a next-generation robotic HIFU system, and continued to report clinical and commercial progress in the U.S. market. In March 2026, the company reported record fourth-quarter and full-year 2025 HIFU revenue, highlighted continued growth in Focal One system placements and U.S. procedures, and reiterated 2026 guidance pointing to further expansion of the core HIFU business. For investors, EDAP remains a specialized growth story in medical technology, with key watchpoints including procedure adoption, regulatory milestones, reimbursement dynamics, and the pace of commercial scaling in the United States.
